The WD40 domain is required for LRRK2 neurotoxicity

PLoS ONE

Volumn 4, Issue 12, 2009, Pages

  Jorgensen, Nathan D ^a   Peng, Yong ^a   Ho, Cherry C Y ^a   Rideout, Hardy J ^a   Petrey, Donald ^a   Liu, Peng ^a   Dauer, William T ^b  

^a NewYork Presbyterian Hospital   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; NEUROTOXIN; PROTEIN SERINE THREONINE KINASE;

ANIMAL CELL; ARTICLE; AUTOPHOSPHORYLATION; COMPLEX FORMATION; DIMERIZATION; ENZYME ACTIVITY; ENZYME STRUCTURE; HUMAN; HUMAN CELL; MOUSE; MUTATION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PROTEIN DOMAIN; ANIMAL; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; GENE DELETION; MOLECULAR WEIGHT; PHOSPHORYLATION; PROTEIN MULTIMERIZATION; PROTEIN TERTIARY STRUCTURE; STRUCTURAL HOMOLOGY; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELL LINE; HUMANS; MICE; MODELS, MOLECULAR; MOLECULAR WEIGHT; NEUROTOXINS; PHOSPHORYLATION; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; SEQUENCE DELETION; STRUCTURAL HOMOLOGY, PROTEIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77949514432     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008463     Document Type: Article

References (45)

1. Nussbaum RL, Polymeropoulos MH (1997) Genetics of Parkinson's disease. Hum Mol Genet 6: 1687-1691.
2. de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, et al. (1997) Prevalence of parkinsonism and Parkinson's disease in Europe: the EURO- PARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 62: 10-15.
3. Muir T, Zegarac M (2001) Societal costs of exposure to toxic substances: economic and health costs of four case studies that are candidates for environmental causation. Environ Health Perspect 109 Suppl 6: 885-903.
4. Klein C, Lohmann-Hedrich K (2007) Impact of recent genetic findings in Parkinson's disease. Curr Opin Neurol 20: 453-464.
5. Hardy J, Cai H, Cookson MR, Gwinn-Hardy K, Singleton A (2006) Genetics of Parkinson's disease and parkinsonism. Ann Neurol 60: 389-398.
6. Dawson TM, Dawson VL (2003) Rare genetic mutations shed light on the pathogenesis of Parkinson disease. J Clin Invest 111: 145-151.
7. Khan NL, Jain S, Lynch JM, Pavese N, Abou-Sleiman P, et al. (2005) Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 128: 2786-2796.
8. Farrer MJ (2007) Lrrk2 in the limelight! Neurology 69: 1732-1733.
9. Moore DJ, West AB, Dawson VL, Dawson TM (2005) Molecular pathophys- iology of Parkinson's disease. Annu Rev Neurosci 28: 57-87.
10. Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, et al. (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 9: 1231-1233.
11. Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, et al. (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 23: 329-341.
12. Lewis PA, Greggio E, Beilina A, Jain S, Baker A, et al. (2007) The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem Biophys Res Commun 357: 668-671.
13. Li X, Tan YC, Poulose S, Olanow CW, Huang XY, et al. (2007) Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J Neurochem 103: 238-247.
14. Guo L, Gandhi PN, Wang W, Petersen RB, Wilson-Delfosse AL, et al. (2007) The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp Cell Res 313: 3658-3670.
15. Imai Y, Gehrke S, Wang HQ, Takahashi R, Hasegawa K, et al. (2008) Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J.
16. Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, et al. (2007) LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J 405: 307-317.
17. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, et al. (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 102: 16842-16847.
18. Greggio E, Zambrano I, Kaganovich A, Beilina A, Taymans JM, et al. (2008) The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J Biol Chem 283: 16906-16914.
19. van Egmond WN, Kortholt A, Plak K, Bosgraaf L, Bosgraaf S, et al. (2008) Intramolecular activation mechanism of the dictyostelium LRRK2-homolog Roco protein GbpC. J Biol Chem.
20. Deng J, Lewis PA, Greggio E, Sluch E, Beilina A, et al. (2008) Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc Natl Acad Sci U S A 105: 1499-1504.
21. Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP, Gallo KA (2006) LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci 29: 286-293.
22. Greggio E, Lewis PA, van der Brug MP, Ahmad R, Kaganovich A, et al. (2007) Mutations in LRRK2/dardarin associated with Parkinson disease are more toxic than equivalent mutations in the homologous kinase LRRK 1. J Neurochem 102: 93-102.
23. Gloeckner CJ, Kinkl N, Schumacher A, Braun RJ, O'Neill E, et al. (2006) The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet 15: 223-232.
24. Gotthardt K, Weyand M, Kortholt A, Van Haastert PJ, Wittinghofer A (2008) Structure of the Roc-COR domain tandem of C. tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinase. EMBO J 27: 2352.
25. Farrer MJ, Stone JT, Lin CH, Dachsel JC, Hulihan MM, et al. (2007) Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. Parkinsonism Relat Disord 13: 89-92.
26. Funayama M, Li Y, Tomiyama H, Yoshino H, Imamichi Y, et al. (2007) Leucine-rich repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population. Neuroreport 18: 273-275.
27. Tan EK, Zhao Y, Skipper L, Tan MG, Di Fonzo A, et al. (2007) The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence. Hum Genet 120: 857-863.
28. Marin I (2008) Ancient origin of the Parkinson disease gene LRRK 2. J Mol Evol 67: 41-50.
29. Petrey D, Xiang Z, Tang CL, Xie L, Gimpelev L, et al. (2003) Using multiple structure alignments, fast model building, and energetic analysis in fold recognition and homology modeling. Proteins: Structure, Function, and Genetics 53: 430-435.
30. Ho CC, Rideout HJ, Ribe E, Troy CM, Dauer WT (2009) The Parkinson disease protein leucine-rich repeat kinase 2 transduces death signals via Fas- associated protein with death domain and caspase-8 in a cellular model of neurodegeneration. J Neurosci 29: 1011-1016.
31. Dachsel JC, Taylor JP, Mok SS, Ross OA, Hinkle KM, et al. (2007) Identification of potential protein interactors of Lrrk 2. Parkinsonism Relat Disord 13: 382-385.
32. Wang L, Xie C, Greggio E, Parisiadou L, Shim H, et al. (2008) The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine- rich repeat kinase 2. J Neurosci 28: 3384-3391.
33. Gandhi PN, Wang X, Zhu X, Chen SG, Wilson-Delfosse AL (2008) The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. J Neurosci Res 86: 1711-1720.
34. Di Fonzo A, Wu-Chou YH, Lu CS, van Doeselaar M, Simons EJ, et al. (2006) A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. Neurogenetics 7: 133-138.
35. Korr D, Toschi L, Donner P, Pohlenz HD, Kreft B, et al. (2006) LRRK1 protein kinase activity is stimulated upon binding of GTP to its Roc domain. Cell Signal 18: 910-920.
36. Taylor JP, Hulihan MM, Kachergus JM, Melrose HL, Lincoln SJ, et al. (2007) Leucine-rich repeat kinase 1: a paralog of LRRK2 and a candidate gene for Parkinson's disease. Neurogenetics 8: 95-102.
37. Iaccarino C, Crosio C, Vitale C, Sanna G, Carri MT, et al. (2007) Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum Mol Genet 16: 1319-1326.
38. Yu L, Gaitatzes C, Neer E, Smith TF (2000) Thirty-plus functional families from a single motif. Protein Sci 9: 2470-2476.
39. Smith TF, Gaitatzes C, Saxena K, Neer EJ (1999) The WD repeat: a common architecture for diverse functions. Trends Biochem Sci 24: 181-185.
40. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, et al. (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucl Acids Res 25: 3389-3402.
41. Tang CL, Xie L, Koh IY, Posy S, Alexov E, et al. (2003) On the role of structural information in remote homology detection and sequence alignment: new methods using hybrid sequence profiles. Journal of Molecular Biology 334: 1043-1062.
42. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al. (2000) The Protein Data Bank. Nucleic Acids Research 28: 235-242.
43. Zhou H, Zhou Y (2002) Distance-scaled, finite ideal-gas reference state improves structure-derived potentials of mean force for structure selection and stability prediction.[erratum appears in Protein Sci. 2003 Sep;12(9):2121]. Protein Science 11: 2714-2726.
44. Rideout HJ, Stefanis L (2002) Proteasomal inhibition-induced inclusion formation and death in cortical neurons require transcription and ubiquitina- tion. Mol Cell Neurosci 21: 223-238.
45. Jorgensen ND, Andresen JM, Pitt JE, Swenson MA, Zoghbi HY, et al. (2007) Hsp70/Hsc70 regulates the effect phosphorylation has on stabilizing ataxin-1. J Neurochem 102: 2040-2048.